OncoMatch/Clinical Trials/NCT06229912
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
Is NCT06229912 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Revumenib for leukemia.
Treatment: Revumenib — To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Biomarker criteria
Required: KMT2A (MLL) partial tandem duplication
KMT2A-PTD = Normal karyotype
Required: NPM1 NPM1-MLF1 fusion
NPM1-MLF1 = t(3;5)(q25;q34)
Required: NUP98 rearrangement
NUP98r = 11p15 rearrangements
Required: SET SET-NUP214 fusion
SET-NUP214 = t(9;9)(q34;q34)
Required: RUNX1 RUNX1-EVI1 fusion
RUNX1-EVI1 = t(3;21)(q26;q22)
Required: KAT6A MYST3-CREBBP fusion
MYST3-CREBBP = t(8;16)(p11;p13)
Required: CDX2 CDX2-ETV6 fusion
CDX2-ETV6 = t(12;13)(p13;q12)
Required: PICALM CALM-AF10 fusion
CALM-AF10 = t(10;11)(p13;q14-21)
Required: MN1 MN1-ETV6 fusion
MN1-ETV6 = t(12;22)(p13;q12)
Required: UBTF UBTF-TD
UBTF-TD = Normal karyotype
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: any prior therapy — relapsed or refractory
Relapsed or refractory acute leukemia
Lab requirements
Blood counts
wbc must be below 25,000/ ul at time of enrollment
Kidney function
estimated glomerular filtration rate ≥ 60 ml/min based on local institutional practice for age-appropriate determination
Liver function
direct bilirubin < 1.5x uln unless increase is due leukemic involvement, and ast and/or alt < 3x uln unless considered due to leukemic involvement, in which case direct bilirubin or ast and/or alt < 5x uln will be considered eligible
Cardiac function
baseline ejection fraction must be > 40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center · New York, New York
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06229912 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received any prior therapy.
Does this trial require KMT2A?
Yes, KMT2A partial tandem duplication is a required biomarker for enrollment.
Does this trial require NPM1?
Yes, NPM1 NPM1-MLF1 fusion is a required biomarker for enrollment.
Does this trial require NUP98?
Yes, NUP98 rearrangement is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify